Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

Non-coding RNA Research, published by KEAI PUBLISHING LTD, is a leading open-access journal dedicated to advancing the field of non-coding RNA, a critical component in the landscape of molecular biology and genetics. Established in 2016, this journal aims to provide a platform for the dissemination of high-quality research focusing on the roles, mechanisms, and therapeutic potentials of non-coding RNAs in various biological processes and diseases. With impressive Scopus rankings placing it in the top quartile for both Biochemistry and Medical Biochemistry, as well as notable standings in Genetics and Molecular Biology, Non-coding RNA Research continues to attract contributions from globally recognized experts. The journal's commitment to open access ensures broad visibility and engagement with cutting-edge discoveries, thereby fostering an inclusive scientific dialogue that enhances understanding and innovation in this rapidly evolving field. For researchers and scholars, the opportunity to publish in a Q1 ranked journal not only validates their work but also enhances its impact, making Non-coding RNA Research an indispensable resource for anyone interested in the intricate workings of non-coding RNA.

The Journal of Cell Communication and Signaling is a prestigious academic journal published by Springer, focused on advancing the understanding of cellular communication mechanisms and signaling pathways. Since its inception in 2007, this journal has established itself as a leading platform in the field, with a strong impact reflected in its 2023 categorizations: Q1 in Biochemistry, Q2 in Cell Biology, and Q2 in Molecular Biology. Researchers from around the globe rely on its rigorous peer-reviewed articles to gain insights into the complex molecular dialogue that underpins various biological processes. With an ISSN of 1873-9601 and E-ISSN of 1873-961X, the journal is committed to disseminating high-quality research that informs both academic studies and practical applications in biotechnology and medicine. Although not an open access publication, it provides essential resources tailored for professionals, students, and researchers, enhancing their knowledge of critical signaling pathways that drive health and disease. The journal is located in the Netherlands, at VAN GODEWIJCKSTRAAT 30, DORDRECHT, and stands out in the field, boasting impressive ranks among its peers in the Scopus database.

International Journal of Biological Sciences (ISSN: 1449-2288, E-ISSN: 1449-2288) is a premier open-access journal published by IVYSPRING INTERNATIONAL PUBLISHING since 2005, located in Australia. With a commitment to advancing knowledge in the life sciences, this journal covers a wide spectrum of disciplines, including Applied Microbiology and Biotechnology, Cell Biology, Developmental Biology, Ecology, Evolution, Behavior and Systematics, and Molecular Biology, earning a distinguished Q1 ranking in these fields as of 2023. It stands out with exceptional Scopus rankings, placing in the top ranks across multiple categories, such as the 98th percentile in Ecology, Evolution, Behavior and Systematics and the 94th percentile in Applied Microbiology and Biotechnology. The journal fosters an open access philosophy, ensuring that research findings are readily available to the scientific community and the public, and invites original research articles, reviews, and commentaries. With its mission to disseminate high-quality research, the International Journal of Biological Sciences serves as an essential resource for researchers, professionals, and students seeking to deepen their understanding and drive innovation in biological sciences.

Cell Death Discovery, published by Springer Nature, is a distinguished open-access journal dedicated to advancing the field of cell death research. Since its inception in 2015, the journal has rapidly established itself as a premier platform for high-quality research, currently holding a remarkable position in the Q1 quartiles across multiple categories, including Cancer Research, Cell Biology, Cellular and Molecular Neuroscience, and Immunology. With an impact factor reflecting its significant contribution to the scientific community, Cell Death Discovery invites submissions that explore the molecular mechanisms of cell death and its implications across various biomedical fields. The journal's open-access model ensures that groundbreaking research is accessible to a global audience, facilitating collaboration and dissemination among researchers, professionals, and students alike. Located in the UK, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, the journal continues to support innovative scholarship and foster a deeper understanding of the processes behind cell viability, development, and disease.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.